中国仓鼠卵巢细胞
生物制药
单克隆抗体
生物过程
细胞培养
生物技术
生物
细胞生物学
计算生物学
抗体
免疫学
遗传学
古生物学
作者
Shazid Md. Sharker,Atiqur Rahman
出处
期刊:Current Drug Discovery Technologies
[Bentham Science]
日期:2021-05-01
卷期号:18 (3): 354-364
被引量:34
标识
DOI:10.2174/1570163817666200312102137
摘要
Most of the clinical approved protein-based drugs or under clinical trials have a profound impact on the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of the therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to enhance specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will focus on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.
科研通智能强力驱动
Strongly Powered by AbleSci AI